Why are second-generation H1-antihistamines minimally sedating?

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• H1-antihistamines are crucial for managing allergic conditions like asthma and urticaria.
• First-generation H1-antihistamines exhibit significant sedative effects, unlike their second-generation counterparts.
• The mechanism behind the reduced sedation of second-generation antihistamines remained unclear until the late 1990s.

Purpose of the Study:

• To review the interactions between P-glycoprotein and common second-generation H1-antihistamines.
• To explore other factors contributing to the minimal sedating properties of second-generation H1-antihistamines.
• To elucidate the role of P-glycoprotein in the reduced central nervous system effects of newer antihistamines.

Main Methods:

• Literature review focusing on P-glycoprotein interactions with H1-antihistamines.
• Analysis of studies investigating drug efflux mechanisms at the blood-brain barrier.
• Examination of the biochemical structure and function of P-glycoprotein.

Main Results:

• Second-generation H1-antihistamines are identified as substrates of P-glycoprotein.
• P-glycoprotein acts as an efflux pump at the blood-brain barrier, limiting antihistamine entry into the brain.
• This efflux mechanism significantly reduces central nervous system exposure and subsequent sedation.

Conclusions:

• P-glycoprotein is a key determinant of the non-sedating profile of second-generation H1-antihistamines.
• Understanding these interactions aids in the development of more targeted and effective allergy treatments.
• Further research into other contributing factors may reveal additional therapeutic strategies.